Tag: Mesothelioma News

Clinical Cancer Research , Vol. 18, No. 17. , pp. 4646-4656, doi:10.1158/1078-0432.ccr-12-0599 To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

A new type of immuno-oncology treatment from Novartis AG proved safe in a tiny study of three types of solid tumors, but the trial included too few patients and used too small a dose of the experimental product to prove effectiveness, according to data…

For some time now solid tumours has been seen as the next big battleground for CAR-T therapy, but based on the underwhelming early data released yesterday at the AACR meeting the best that can be said is that the jury is still out. A very early trial o…

One of Devon’s largest law firms is expanding its national-level expertise with the appointment of a consultant who comes from a top 100 London law firm. Terry Lee has joined Wollen Michelmore as a consultant solicitor in the civil dispute resolution d…

Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers at the Perelman School of Medicine at the University of…

Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers at the Perelman School of Medicine at the University of…

Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers. The data adds to a growing body of research showing the promise of CAR T cell technology.

Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers. The data adds to a growing body of research showing the promise of CAR T cell technology.

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall,…

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall,…

The early findings presented showed an overall response rate of 28 percent with pembrolizumab in patients with tumours that expressed PD-L1. Additionally, 48 percent of patients had stable disease, resulting in a disease control rate of 76 percent.

The early findings presented showed an overall response rate of 28 percent with pembrolizumab in patients with tumours that expressed PD-L1. Additionally, 48 percent of patients had stable disease, resulting in a disease control rate of 76 percent.